Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

In a recent interview, Stacy Loeb, MD, MSc, PhD (Hon), a professor in the departments of urology and population health at NYU Grossman School of Medicine and Perlmutter Cancer Center in New York, New ...

The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Currently, several FDA-approved agents treat BCG-unresponsive carcinoma in situ (CIS), with or without papillary disease. Pembrolizumab, a single-agent checkpoint inhibitor, has a complete response ...

Urologists from Cleveland Clinic recently collaborated across borders to perform the world’s first remotely conducted robot–assisted high-intensity focused ultrasound (HIFU) focal therapy procedure ...

Elterman noted that the interest in FITs is only going to continue to grow. “We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of ...

Key Takeaways Non-Hispanic Black and Latinx patients with prostate cancer are less likely to receive PSMA-PET imaging than non-Hispanic White patients, indicating racial/ethnic disparities. The study ...

Bedke explained, “I think the important message is that we have no specific subgroup which will have a more pronounced benefit of EV+P if compared to the platinum-based chemotherapy. Selecting ...

Improving Clinical Trial Diversity Key Themes: A multistakeholder approach is required (patients, communities, clinicians, payers, industry). Community outreach initiatives are essential for building ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...